openPR Logo
Press release

Dilated Cardiomyopathy Therapeutics Market Company Analysis and Forecast to 2020

06-21-2017 01:52 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Dilated Cardiomyopathy Therapeutics Market Company Analysis

Dilated cardiomyopathy (DCM) is a significant cause of heart failure and a leading indication for heart transplant among children and adults across the globe. This condition is characterized by enlargement of ventricular chamber, thinning of heart walls and inability to sufficiently pump blood throughout the body. Dilated cardiomyopathy can develop at any age but is more common among people aged between 20 years to 60 years. Genetic inheritance is found to affect about 30% to 40% of the total DCM patients. Single gene mutations in either the structural proteins of the myocyte, such as dystrophin, metavinculin, and lamin, or of mitochondrial DNA are also a prominent cause of DCM. Other factors such as diabetes, thyroid disorder, alcoholism, viral infections of the heart and heart valve abnormalities can also lead to dilated cardiomyopathy. Moreover, according to the Pediatric Cardiomyopathy Registry, DCM occurs at a rate of 6 per million children. It is commonly diagnosed in younger children with an average age of diagnosis at 2 years.

Read the Comprehensive Overview of Dilated Cardiomyopathy Therapeutics Market: http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

The global dilated cardiomyopathy therapeutics market is studied from two perspectives i.e. by drug class and by geography. Till date, there is no FDA approved drug specifically for dilated cardiomyopathy treatment. Owing to the aforementioned fact, the drug classes used in treatment of dilated cardiomyopathy are essentially the same as that for treatment of congestive heart failure. Some of the widely prescribed drug classes in dilated cardiomyopathy treatment encompass aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta blockers. Angiotensin II receptor blockers acquired the largest market share by revenue in 2013, followed by beta blockers. This is attributed to high demand for block buster drugs in dilated cardiomyopathy treatment especially in the developed regions such as North America and Europe. Aldosterone antagonists recorded high growth rate due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which in turn would positively impact market growth.

Rising incidences of congestive heart failure across the globe is a prominent growth driver for dilated cardiomyopathy therapeutics market as DCM is one of the leading causes of heart failure. Globally, dilated cardiomyopathy accounts for approximately 30% to 40% of the total congestive heart failure cases each year. Owing to the alarming rise in incidences of congestive heart failure, several companies have initiated clinical trial studies to develop therapeutics specifically for dilated cardiomyopathy. For instance, Array BioPharma in 2015 is conducting a phase II study for its drug candidate ARRY-371797 for DCM treatment. Additionally, Celladon Corporation in 2014 completed its phase II study of MYDICAR for dilated cardiomyopathy treatment. Success of these clinical studies will boost the growth and demand for dilated cardiomyopathy therapeutics market in forthcoming years. However, promising gene therapy and availability of implantable devices (implantable cardioverter defibrillators (ICDs), heart pumps and pacemakers) are major restraints to the DCM therapeutics market.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293

Geographically, dilated cardiomyopathy therapeutics market is studied for four regions: North America, Europe, Asia Pacific and the Rest of the World. In terms of revenue, North America accounted for the largest market share in 2013 owing to rising incidences of congestive heart failure and high acceptance of branded drugs. In the U.S., DCM is prevalent in approximately five to eight people out of every 100,000 people. In Canada, heart failure affects over 1% of the total population and is responsible for about 9% of all the deaths. Asia Pacific and Rest of the World markets are the fastest growing markets due to rising economic standards, growing disposable income and high demand for generic drugs. Key players in the global DCM market include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Vericel Corporation.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dilated Cardiomyopathy Therapeutics Market Company Analysis and Forecast to 2020 here

News-ID: 590089 • Views: 167

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for DCM

Dilated Cardiomyopathy (DCM) Therapeutics Market Research and Forecast 2020-2026
The global dilated cardiomyopathy (DCM) therapeutics market is anticipated to grow with a significant CAGR of 8% during the forecast period. DCM is one of the prevalent causes of heart failure in adult patients and represents the most common diagnosis leading to a heart transplant in children. The advancements in healthcare and the introduction of new modern techniques are reducing the challenges for the treatment of pediatric DCM. In addition
Engine Blocks Market Analysis Data of Leading Player’s 2018-2025: Weber Automo …
HTF MI recently introduced Global Engine Blocks Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Weber Automotive, Honda, DCM Engineering, KARAN EXPORTS, CEMEX, Yamuna Automotive, TCU,
Global Rotogravure Printing Machine Market 2018 - Uteco, Hsing Wei, Toshiba Mach …
Apex Market Reports, recently published a detailed market research study focused on the “Rotogravure Printing Machine Market” across the global, regional and country level. The report provides 360° analysis of “Rotogravure Printing Machine Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Rotogravure
Dynamic Case Management (DCM) Market Investment Research Report 2025
Dynamic or Advanced Case Management (DCM) can be defined as the process of capturing and processing unstructured data with the use of various technologies. The collective information about a particular instance, such as a problem, incident or a company is called a case. Traditional workflows which are operational across legacy systems are not capable of handling the slightest of change in the processes. Although, automation and optimization of critical business
DCM Signs Irish Champion Lucca Allen
Driver Club Management (DCM) has signed junior racing driver Lucca Allen to its 2018 driver line-up. Allen becomes the youngest driver to be signed by DCM as he warms up for his first full season in single-seaters. At 15 years of age, DCM scouted Allen for his unique assets and his fast rate of development to date. The young Irishman from Cork has risen through national and regional karting championships with
Rotogravure Printing Machine Market 2017 - BOBST, DCM-ATN, Rotatek, KKA GmbH
Apex Research, recently published a detailed market research study focused on the "Rotogravure Printing Machine Market" across the global, regional and country level. The report provides 360° analysis of "Rotogravure Printing Machine Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Rotogravure Printing Machine industry, and estimates the future trend of Rotogravure